Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates

Published on Jun 20, 2016in Bioconjugate Chemistry4.031
· DOI :10.1021/ACS.BIOCONJCHEM.6B00117
Jose F. Ponte10
Estimated H-index: 10
(ImmunoGen, Inc.),
Xiuxia Sun6
Estimated H-index: 6
(ImmunoGen, Inc.)
+ 13 AuthorsJohn M. Lambert52
Estimated H-index: 52
(ImmunoGen, Inc.)
Sources
Abstract
Antibody-drug conjugates (ADCs) have become a widely investigated modality for cancer therapy, in part due to the clinical findings with ado-trastuzumab emtansine (Kadcyla). Ado-trastuzumab emtansine utilizes the Ab-SMCC-DM1 format, in which the thiol-functionalized maytansinoid cytotoxic agent, DM1, is linked to the antibody (Ab) via the maleimide moiety of the heterobifunctional SMCC linker. The pharmacokinetic (PK) data for ado-trastuzumab emtansine point to a faster clearance for the ADC than for total antibody. Cytotoxic agent release in plasma has been reported with nonmaytansinoid, cysteine-linked ADCs via thiol-maleimide exchange, for example, brentuximab vedotin. For Ab-SMCC-DM1 ADCs, however, the main catabolite reported is lysine-SMCC-DM1, the expected product of intracellular antibody proteolysis. To understand these observations better, we conducted a series of studies to examine the stability of the thiol-maleimide linkage, utilizing the EGFR-targeting conjugate, J2898A-SMCC-DM1, and compari...
📖 Papers frequently viewed together
635 Citations
228 Citations
241 Citations
References31
Newest
#1Mallory R. Gordon (UMass: University of Massachusetts Amherst)H-Index: 4
#2Mine Canakci (UMass: University of Massachusetts Amherst)H-Index: 5
Last. Sankaran Thayumanavan (UMass: University of Massachusetts Amherst)H-Index: 67
view all 6 authors...
Antibody–drug conjugates have attracted a great amount of attention as a therapeutic strategy for diseases where targeting specific tissues and cells are critical components, such as in cancer therapy. Although promising, the number of approved ADC drugs is relatively limited. This emanates from the challenges associated with generating the conjugates and the complexities associated with the stability requirements for these conjugates during circulation and after reaching the target. Here, we pr...
49 CitationsSource
#1Wayne C. Widdison (ImmunoGen, Inc.)H-Index: 15
#2Sharon D. Wilhelm (ImmunoGen, Inc.)H-Index: 10
Last. Ravi V. J. Chari (ImmunoGen, Inc.)H-Index: 30
view all 10 authors...
Several antibody–maytansinoid conjugates (AMCs) are in clinical trials for the treatment of various cancers. Each of these conjugates can be metabolized by tumor cells to give cytotoxic maytansinoid metabolites that can kill targeted cells. In preclinical studies in mice, the cytotoxic metabolites initially formed in vivo are further processed in the mouse liver to give several oxidized metabolic species. In this work, the primary AMC metabolites were synthesized and incubated with human liver m...
14 CitationsSource
#1Katharine C. Lai (ImmunoGen, Inc.)H-Index: 9
#2Jutta Deckert (ImmunoGen, Inc.)H-Index: 12
Last. John M. Lambert (ImmunoGen, Inc.)H-Index: 52
view all 7 authors...
Purpose Many antibody-drug conjugates (ADCs) become active only after antigen-mediated internalization and release of the cytotoxic agent via antibody degradation. Quantifying these processes can provide critical information on the suitability of a particular receptor target or antibody for ADC therapy by providing insight into the amount of cytotoxic agent released. We describe a simple and inexpensive radiolabel assay to monitor this process in cultured cancer cells.
8 CitationsSource
#1Shaun D. FontaineH-Index: 9
#2Ralph ReidH-Index: 22
Last. Daniel V. SantiH-Index: 76
view all 5 authors...
Michael-addition of a thiol to a maleimide is commonly used for bioconjugation of drugs to macromolecules. Indeed, both current FDA-approved antibody–drug conjugates—Brentuximab vedotin and Trastuzumab emtansine—and one approved PEGylated conjugate—Cimzia—contain a thiol–maleimide adduct. However, the ultimate in vivo fate of such adducts is to undergo disruptive cleavage by thiol exchange or stabilizing ring opening. Therapeutic efficacy of a conjugate can be compromised by thiol exchange and t...
164 CitationsSource
#1L. Nathan Tumey (Pfizer)H-Index: 20
#2Manoj CharatiH-Index: 5
Last. Edmund I. GrazianiH-Index: 21
view all 12 authors...
The stability of the connection between the antibody and the toxin can have a profound impact on ADC safety and efficacy. There has been increasing evidence in recent years that maleimide-based ADCs are prone to payload loss via a retro-Michael type reaction. Herein, we report a mild method for the hydrolysis of the succinimide-thioether ring which results in a “ring-opened” linker. ADCs containing this hydrolyzed succinimide linker show equivalent cytotoxicity, improved in vitro stability, impr...
106 CitationsSource
#1Robert P. Lyon (Seattle Genetics)H-Index: 12
#2Jocelyn R. Setter (Seattle Genetics)H-Index: 6
Last. Peter D. SenterH-Index: 72
view all 11 authors...
A new method for linking antibodies to drugs produces conjugates with improved stability and efficacy.
228 CitationsSource
#1Laleh Amiri-Kordestani (CDER: Center for Drug Evaluation and Research)H-Index: 12
#1Laleh Amiri-Kordestani (CDER: Center for Drug Evaluation and Research)H-Index: 20
Last. Patricia Cortazar (CDER: Center for Drug Evaluation and Research)H-Index: 9
view all 28 authors...
On February 22, 2013, the FDA licensed ado-trastuzumab emtansine (Kadcyla; Genentech, Inc.) for use as a single agent for the treatment of patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. The clinical basis for licensure was a phase III trial in 991 patients with HER2-positive MBC that randomly allocated patients to receive ado-trastuzumab emtansine ( n = 495) or l...
148 CitationsSource
Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker. Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active derivative of DM1 is subsequently released by proteolytic degradation of the antibody moiety within the lysos...
246 CitationsSource
#1Brendan Bender (Uppsala University)H-Index: 5
#2Douglas D. Leipold (Genentech)H-Index: 14
Last. Lena E. Friberg (Uppsala University)H-Index: 48
view all 6 authors...
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate (ADC) therapeutic for treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers. The T-DM1 dose product contains a mixture of drug-to-antibody ratio (DAR) moieties whereby the small molecule DM1 is chemically conjugated to trastuzumab antibody. The pharmacokinetics (PK) underlying this system and other ADCs are complex and have not been elucidated. Accordingly, we have developed two PK modeling approaches from precli...
58 CitationsSource
#1Claudia M. CremersH-Index: 9
#2Ursula Jakob (UM: University of Michigan)H-Index: 63
Maintenance of the cellular redox balance is crucial for cell survival. An increase in reactive oxygen, nitrogen, or chlorine species can lead to oxidative stress conditions, potentially damaging DNA, lipids, and proteins. Proteins are very sensitive to oxidative modifications, particularly methionine and cysteine residues. The reversibility of some of these oxidative protein modifications makes them ideally suited to take on regulatory roles in protein function. This is especially true for disu...
205 CitationsSource
Cited By33
Newest
#1Sai Kiran Sharma (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
#2Pierre Adumeau (CUNY: City University of New York)H-Index: 9
Last. Brian M. Zeglis (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 36
view all 16 authors...
Delta-like ligand 3 (DLL3) is a therapeutic target for the treatment of small cell lung cancer, neuroendocrine prostate cancer, and isocitrate dehydrogenase mutant glioma. In the clinic, DLL3-targeted 89Zr-immunoPET has the potential to aid in the assessment of disease burden and facilitate the selection of patients suitable for therapies that target the antigen. The overwhelming majority of 89Zr-labeled radioimmunoconjugates are synthesized via the random conjugation of desferrioxamine (DFO) to...
Source
#1Zheng Su (SPU: Shenyang Pharmaceutical University)
#2Xiao DianH-Index: 1
Last. Li Song (SPU: Shenyang Pharmaceutical University)H-Index: 1
view all 8 authors...
Abstract Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody‒drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major influence on the fate of ADCs. An ideal linker should be stable in the circulatory system and release the cytotoxic payload specifically in the tumor. However, existing linkers often release payloads nonspecifically and inevitably lead to off-target toxicity. This defect is becoming an ...
Source
#1Chang Chun-Kai (NTU: National Taiwan University)
#2Pei-Fang Chiu (NTU: National Taiwan University)H-Index: 1
Last. Pi-Hui Liang (NTU: National Taiwan University)H-Index: 16
view all 9 authors...
Overexpression of glucose transporters (GLUTs) in colorectal cancer cells is associated with 5-fluorouracil (1, 5-FU) resistance and poor clinical outcomes. We designed and synthesized a novel GLUT-targeting drug conjugate, triggered by glutathione in the tumor microenvironment, that releases 5-FU and GLUTs inhibitor (phlorizin (2) and phloretin (3)). Using an orthotopic colorectal cancer mice model, we showed that the conjugate exhibited better antitumor efficacy than 5-FU, with much lower expo...
Source
#1Peter A. Szijj (UCL: University College London)H-Index: 5
#2Vijay Chudasama (UCL: University College London)H-Index: 30
Bispecific antibodies (bsAbs) target two different epitopes. These are an up-and-coming class of biologics, with two such therapeutics (emicizumab and blinatumomab) FDA approved and on the market, and many more in clinical trials. While the first reported bsAbs were constructed by chemical methods, this approach has fallen out of favour with the advent of modern genetic engineering techniques and, nowadays, the vast majority of bsAbs are produced by protein engineering. However, in recent years,...
Source
#1Erol C. Vatansever (A&M: Texas A&M University)H-Index: 5
#2Jeffrey Che-Wei Kang (A&M: Texas A&M University)H-Index: 1
Last. Wenshe R. Liu (A&M: Texas A&M University)H-Index: 31
view all 5 authors...
As a versatile reaction for bioconjugation, Cu(I)-catalyzed alkyne-azide cycloaddition (CuAAC) has enormous potential in the synthesis of antibody-drug conjugates (ADCs). In order to optimize CuAAC-based ADC synthesis, we characterized kinetically different formulation processes by mimicking ADC synthesis using small molecules and subsequently revealed unique kinetic behaviors of different combinations of alkyne and azide conditions. Our results indicate that under ADC synthesis conditions, for ...
Source
#1Lillian SkidmoreH-Index: 1
#2Sukumar SakamuriH-Index: 1
Last. Feng TianH-Index: 11
view all 16 authors...
First generation antibody drug conjugates (ADCs) are heterogeneous mixtures that have shown clinical benefit, but generally exhibited safety issues and a narrow therapeutic window due in part to off-target toxicity caused by ADC instability. ARX788 is a next generation, site-specific anti-HER2 ADC that utilizes a unique non-natural amino acid enabled conjugation technology and a non-cleavable Amberstatin (AS269) drug-linker to generate a homogeneous ADC with a drug-to-antibody ratio of 1.9. ARX7...
6 CitationsSource
#1Jonatan Dewulf (University of Antwerp)H-Index: 3
#2Karuna Adhikari (University of Antwerp)H-Index: 2
Last. Filipe Elvas (University of Antwerp)H-Index: 13
view all 5 authors...
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are molecular imaging strategies that typically use radioactively labeled ligands to selectively visualize molecular targets. The nanomolar sensitivity of PET and SPECT combined with the high specificity and affinity of monoclonal antibodies have shown great potential in oncology imaging. Over the past decades a wide range of radio-isotopes have been developed into immuno-SPECT/PET imaging agents, made poss...
2 CitationsSource
#1Mark B. Richardson (UCI: University of California, Irvine)H-Index: 6
#2Kristin N. Gabriel (UCI: University of California, Irvine)H-Index: 3
Last. Gregory A. Weiss (UCI: University of California, Irvine)H-Index: 2
view all 16 authors...
Advances in bioconjugation, the ability to link biomolecules to each other, small molecules, surfaces, and more, can spur the development of advanced materials and therapeutics. We have discovered that pyrocinchonimide, the dimethylated analog of maleimide, undergoes a surprising transformation with biomolecules. The reaction targets amines and involves an imide transfer, which has not been previously reported for bioconjugation purposes. Despite their similarity to maleimides, pyrocinchonimides...
Source
#1Chiara Da Pieve (ICR: Institute of Cancer Research)H-Index: 3
#2Ata Makarem (DKFZ: German Cancer Research Center)H-Index: 5
Last. Gabriela Kramer-Marek (ICR: Institute of Cancer Research)H-Index: 22
view all 6 authors...
Site-selective bioconjugation of cysteine-containing peptides and proteins is currently achieved via a maleimide–thiol reaction (Michael addition). When maleimide-functionalized chelators are used and the resulting bioconjugates are subsequently radiolabeled, instability has been observed both during radiosynthesis and post-injection in vivo, reducing radiochemical yield and negatively impacting performance. Recently, a phenyloxadiazolyl methylsulfone derivative (PODS) was proposed as an alterna...
1 CitationsSource
#1Marc-André KasperH-Index: 8
#2Marcus Gerlach (Center for Integrated Protein Science Munich)H-Index: 3
view all 11 authors...
Herein, the application of N-hydroxysuccinimide-modified phosphonamidate building blocks for the incorporation of cysteine-selective ethynylphosphonamidates into lysine residues of proteins, followed by thiol addition with small molecules and proteins, is reported. It is demonstrated that the building blocks significantly lower undesired homo-crosslinking side products that can occur with commonly applied succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) under physiological pH. ...
3 CitationsSource